LEADER 05257nam 22008175 450 001 9910409690903321 005 20220629152811.0 010 $a3-030-43855-4 024 7 $a10.1007/978-3-030-43855-5 035 $a(CKB)4100000011273783 035 $a(MiAaPQ)EBC6194054 035 $a(DE-He213)978-3-030-43855-5 035 $a(PPN)248396625 035 $a(EXLCZ)994100000011273783 100 $a20200508d2020 u| 0 101 0 $aeng 135 $aurcnu|||||||| 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 10$aPreclinical Evaluation of Antimicrobial Nanodrugs /$fby Juan Bueno 205 $a1st ed. 2020. 210 1$aCham :$cSpringer International Publishing :$cImprint: Springer,$d2020. 215 $a1 online resource (125 pages) 225 1 $aNanotechnology in the Life Sciences,$x2523-8027 311 $a3-030-43854-6 327 $aPreface -- 1. Antimicrobial screening, foundations and interpretation -- 2. Antimicrobial activity of nanomaterials, from selection to application -- 3. Synergy and antagonism, the criteria of the formulation -- 4. In vitro Nanotoxicity, towards the development of safe and effective treatments -- 5. ADMETox, bringing nanotechnology closer to Lipinski's rule of five -- 6. Antimicrobial nanotechnology in preventing the transmission of infectious disease -- 7. Nanotechnology in the discovery of new antimicrobial drugs: is a new scientific revolution possible? -- 8. Nanotechnology beyond the antibiosis -- Index. . 330 $aTranslational medicine addresses the gap between research and the clinical application of new discoveries. To efficiently deliver new drugs to care centers, a preclinical evaluation, both in vitro and in vivo, is required to ensure that the most active and least toxic compounds are selected as well as to predict clinical outcome. Antimicrobial nanomedicines have been shown to have higher specificity in their therapeutic targets and the ability to serve as adjuvants, increasing the effectiveness of pre-existing immune compounds. The design and development of new standardized protocols for evaluating antimicrobial nanomedicines is needed for both the industry and clinical laboratory. These protocols must aim to evaluate laboratory activity and present models of pharmacokinetic-pharmacodynamic and toxicokinetic behavior that predict absorption and distribution. Likewise, these protocols must follow a theranostics approach, be able to detect promising formulations, diagnose the infectious disease, and determine the correct treatment to implement a personalized therapeutic behavior. Given the possibilities that nanotechnology offers, not updating to new screening platforms is inadequate as it prevents the correct application of discoveries, increasing the effect of the valley of death between innovations and their use. This book is structured to discuss the fundamentals taken into account for the design of robust, reproducible and automatable evaluation platforms. These vital platforms should enable the discovery of new medicines with which to face antimicrobial resistance (RAM), one of the great problems of our time. 410 0$aNanotechnology in the Life Sciences,$x2523-8027 606 $aMedical microbiology 606 $aMicrobial genetics 606 $aMicrobial genomics 606 $aNanotechnology 606 $aPharmaceutical technology 606 $aPlant breeding 606 $aPlant biochemistry 606 $aMedical Microbiology$3https://scigraph.springernature.com/ontologies/product-market-codes/B16003 606 $aMicrobial Genetics and Genomics$3https://scigraph.springernature.com/ontologies/product-market-codes/L32010 606 $aNanotechnology$3https://scigraph.springernature.com/ontologies/product-market-codes/Z14000 606 $aPharmaceutical Sciences/Technology$3https://scigraph.springernature.com/ontologies/product-market-codes/B21010 606 $aPlant Breeding/Biotechnology$3https://scigraph.springernature.com/ontologies/product-market-codes/L24060 606 $aPlant Biochemistry$3https://scigraph.springernature.com/ontologies/product-market-codes/L14021 606 $aNanotecnologia$2thub 606 $aFarmacologia$2thub 606 $aMicrobiologia$2thub 608 $aLlibres electrònics$2thub 615 0$aMedical microbiology. 615 0$aMicrobial genetics. 615 0$aMicrobial genomics. 615 0$aNanotechnology. 615 0$aPharmaceutical technology. 615 0$aPlant breeding. 615 0$aPlant biochemistry. 615 14$aMedical Microbiology. 615 24$aMicrobial Genetics and Genomics. 615 24$aNanotechnology. 615 24$aPharmaceutical Sciences/Technology. 615 24$aPlant Breeding/Biotechnology. 615 24$aPlant Biochemistry. 615 7$aNanotecnologia 615 7$aFarmacologia 615 7$aMicrobiologia 676 $a615.792 700 $aBueno$b Juan$4aut$4http://id.loc.gov/vocabulary/relators/aut$01059093 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910409690903321 996 $aPreclinical Evaluation of Antimicrobial Nanodrugs$92504129 997 $aUNINA